Terence M. Williams MD, PhD

home / authors / terence-m-williams-md-phd

Articles

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

Dr. Williams on NLR as a Prognostic Biomarker in NSCLC

Terence M. Williams MD, PhD
May 5th 2020

Terence M. Williams, MD, PhD, discusses research examining a serum biomarker, neutrophil-to-lymphocyte ratio, in non–small cell lung cancer.

Read More

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation

Parotid Node Metastases in Locally Advanced Nasopharyngeal and Oropharyngeal Cancer: Implications for Radiotherapy Target Volume Delineation

Terence M. Williams MD, PhD;Jeffrey M. Vainshtein, MD;Matthew E. Spector, MD;Douglas B. Chepeha, MD;Matthew Stenmark, MD;Avraham Eisbruch, MD
October 5th 2015

The ipsilateral parotidean nodes may be at risk of metastatic involvement when bulky ipsilateral level II metastases and multilevel nodal disease are co-existent, possibly due to retrograde lymphatic drainage.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data